RCUS insider sale notice: 2,831 RSU shares valued at $36.35k
Rhea-AI Filing Summary
Arcus Biosciences (RCUS) Form 144 summary: The notice reports a proposed sale of 2,831 common shares through Morgan Stanley Smith Barney on 09/29/2025 with an aggregate market value of $36,350.04. The shares were acquired as restricted stock units on 12/15/2024 and the filing shows the acquisition and payment date as 12/15/2024. The form also discloses a prior sale during the past three months: a 10b5-1 sale by Alexander Azoy of 1,579 shares on 09/05/2025 for gross proceeds of $18,758.05. The filer certifies they are not aware of undisclosed material adverse information and notes Rule 10b5-1 plan considerations where applicable.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider sale of 2,831 RSU-derived shares valued at ~$36k; disclosed under Form 144, appears routine and not large.
The filing shows a proposed sale of restricted stock unit shares acquired on 12/15/2024. Execution is through a broker on 09/29/2025, with a recent related 10b5-1 sale of 1,579 shares on 09/05/2025. For investors, these transactions are documented disposals by an insider or related party rather than company-level corporate actions. The sizes and proceeds disclosed are explicit and should be compared to outstanding shares and typical insider activity to assess significance.
TL;DR: Form 144 properly discloses proposed sale and RSU origin; includes required insider certification about material nonpublic information.
The notice includes required details: class of securities, broker, acquisition date and nature (RSUs), and prior sales in the past three months. It also contains the representation that the seller does not possess undisclosed material adverse information and references Rule 10b5-1 plan adoption where relevant. Filing completeness supports regulatory compliance for an insider sale.